Loading company
Ernexa Therapeutics Inc.
ERNA · Nasdaq · Healthcare · Biotechnology
Next earnings: November 6, 2026
$3.39-1.6%Sep 28 close
- 1M
- -25.8%
- 6M
- -28.3%
- 1Y
- -87.6%
- 5Y
- -100.0%
ERNA · Nasdaq · Healthcare · Biotechnology
Next earnings: November 6, 2026
$3.39-1.6%Sep 28 close
Ernexa Therapeutics Inc. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $1K | $17K | -94.12% |
| Profit | -$4M | -$3.1M | -27.72% |
| Profit per share | -$3.40 | -$1.23 | -176.42% |
| Free Cash Flow | -$4.2M | -$6.3M | +34.09% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“2022 was a transformational year for Eterna, and we believe that we made significant progress executing on our core strategy of unlocking the potential of mRNA cell engineering through strategic collaboration,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Eterna Therapeutics is a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. Eterna has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing proteins, and the ToRNAdo™ mRNA delivery system from Factor Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are trademarks of Factor Bioscience.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Ernexa Therapeutics Inc.’s Item 2.02 8-K filed March 20, 2023; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Ernexa Therapeutics Inc. has no earnings call transcript available.